Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07108855

Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection

Detection of Upper Gastrointestinal Tumour Depth and Demarcation by Quantified Fluorescence Molecular Endoscopy Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection

Status
Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
University Medical Center Groningen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Endoscopic submucosal dissection (ESD) is a relatively new technique to treat superficial cancers in the upper gastrointestinal (GI) tract. Previous studies reported high en bloc resection rates (95%-97%). However, R0 resection rates (84.5%) suggest that the tumour is not radically removed in all cases, resulting in a risk of tumour recurrence. One of the key challenges is the limited accuracy in determining the depth of cancer invasion. To reduce the risk of tumour recurrence, the endoscopist would greatly benefit from proper and complete visualization of the tumour margin and depth during ESD. Several studies have shown that near-infrared quantified fluorescence molecular endoscopy (qFME) could serve as a red flag detection method and might be a useful imaging tool for tumour demarcation in the upper GI tract. The aim of this study is to evaluate the feasibility of ICG-enhanced near-infrared qFME to determine tumour demarcation and tumour depth in upper GI tumours (e.g. superficial esophageal and/or gastric adenocarcinoma (T1)) during ESD.

Conditions

Interventions

TypeNameDescription
DRUGIndocyanine Green (IC-Green)Systemic administration of indocyanine green during the endoscopic procedure.
DIAGNOSTIC_TESTFluorescence guided identification using indocyanine greenNear-infrared quantified fluorescence molecular endoscopy (qFME) will be used during the endoscopic procedure.

Timeline

Start date
2025-09-01
Primary completion
2027-06-01
Completion
2027-08-01
First posted
2025-08-07
Last updated
2025-08-07

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT07108855. Inclusion in this directory is not an endorsement.